FNCH Stock Overview
A clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Finch Therapeutics Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.00 |
| 52 Week High | US$14.26 |
| 52 Week Low | US$0.80 |
| Beta | 1.28 |
| 1 Month Change | -8.71% |
| 3 Month Change | -0.81% |
| 1 Year Change | 208.99% |
| 3 Year Change | -96.60% |
| 5 Year Change | n/a |
| Change since IPO | -98.28% |
Recent News & Updates
Recent updates
Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration
Sep 01Finch to get back rights to IBD product candidates after Takeda ends collaboration
Aug 25Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M
Aug 11Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Mar 15
Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Dec 15We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully
Aug 28Finch Therapeutics: Gut Instinct Says Buy
Jun 14Shareholder Returns
| FNCH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.3% | -3.6% | -2.4% |
| 1Y | 209.0% | -2.6% | 23.4% |
Return vs Industry: FNCH exceeded the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: FNCH exceeded the US Market which returned 23.4% over the past year.
Price Volatility
| FNCH volatility | |
|---|---|
| FNCH Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FNCH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FNCH's weekly volatility has decreased from 27% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1 | Matt Blischak | www.finchtherapeutics.com |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn’s disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota.
Finch Therapeutics Group, Inc. Fundamentals Summary
| FNCH fundamental statistics | |
|---|---|
| Market cap | US$17.66m |
| Earnings (TTM) | -US$14.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs FNCH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FNCH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.17m |
| Earnings | -US$14.17m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.82 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did FNCH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Finch Therapeutics Group, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Maneka Mirchandaney | Evercore ISI |
| Vernon Bernardino | H.C. Wainwright & Co. |